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Abstract
Background: A recent study has shown that phosphorylated c-Jun (p-c-Jun) interacts with TCF4
to form a complex that cooperatively enhances their transcriptional activity in the presence of β-
Catenin, and that their interaction is critical for mouse intestinal tumorigenesis. To determine the
significance of these three proteins in human colorectal tumors, we analyzed their nuclear
expression by immunohistochemistry.
Methods:  we analyzed their nuclear expression by immunohistochemistry using paraffin-
embedded specimens of 68 resected colorectal tumors, which consisted of 19 adenomas, 14 high-
grade intraepithelial neoplasia (HGINs) and 35 adenocarcinomas. We also analyzed the expression
of MMP7, which has functional AP-1 and TCF binding sites in its promoter.
Results: Expression of p-c-Jun, TCF4 and β-Catenin were significantly higher in adenomas than in
the adjacent normal epithelia. Expression of p-c-Jun and β-Catenin in HGINs and adenocarcinomas
were also significantly higher than in the adjacent normal epithelia. p-c-Jun expression, but not
TCF4 and β-Catenin, was higher in adenomas and HGINs than in adenocarcinomas, in which p-c-
Jun expression was negatively correlated with pT stage progression. Furthermore, significant
correlations of expression were observed between p-c-Jun and TCF4 (r = 0.25, p = 0.04), TCF4
and β-Catenin (r = 0.30, p = 0.01), p-c-Jun and MMP7 (r = 0.26, p = 0.03), and TCF4 and MMP7 (r
= 0.39, p = 0.0008), respectively.
Conclusion: These results suggest that nuclear expression of p-c-Jun, TCF4 and β-Catenin have
important roles in human colorectal tumor development and that p-c-Jun may play a pivotal role in
the earlier stages of tumor development.
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Background
Colorectal tumorigenesis is a multistep process involving
genetic alterations of oncogenes and tumor suppressor
genes, which lead to deregulation of a number of critical
molecular pathways [1,2]. One of the important genetic
abnormalities is the mutation of the adenomatous poly-
posis coli (Apc) tumor suppressor gene, which results in
deregulation of the APC/β-Catenin/T-cell factor 4 (TCF-4)
signaling pathway [1-3]. β-Catenin is a 92 kDa protein
that binds to the cytoplasmic tail of E-cadherin and plays
an important role in the Wnt signal transduction [4,5].
When mutations in the Apc gene or the β-Catenin gene
itself occur, or when the Wnt pathway is up-regulated, β-
Catenin accumulates in the cytoplasm and migrates to the
nucleus [6]. The aberrantly accumulated β-Catenin in the
nucleus activates transcription by forming a complex with
the TCF/LEF HMG box transcription factors family,
including the TCF4, with the net result of the activation of
the target genes that include c-myc, cyclin D1 and c-jun
[2,6,7].
The proto-oncoprotein c-Jun is a major component of
dimeric AP-1 transcription factor [8]. Deregulated expres-
sion of c-Jun transforms rodent fibroblasts [9] depending
on the induction of multiple c-Jun target genes [10-12],
while the cell transformation by various oncogenes
requires an increase of the c-Jun expression [13]. An
important mechanism in the stimulation of the AP-1
function is amino-terminal phosphorylation of c-Jun by
the c-Jun N-terminal kinases (JNKs) [14,15]. Phosphor-
ylated c-Jun (p-c-Jun) is involved in stress-induced apop-
tosis, cellular proliferation and tumorigenesis [16]. A
recent study has shown that p-c-Jun interacts with TCF4 to
form a complex that cooperatively enhances the transcrip-
tional activity in the presence of β-Catenin and that the
interaction dependent on the phosphorylation of c-Jun is
critical for mouse intestinal tumorigenesis to occur [17].
In addition, another recent study also shows physical and
functional cooperation between AP-1 proteins including
c-Jun and β-Catenin for the regulation of TCF-dependent
genes [18]. However, expressions of p-c-Jun in combina-
tion with TCF4 and β-Catenin have not been explored
with regard to human colorectal tumors.
To determine the significance of p-c-Jun, TCF4 and β-Cat-
enin in human colorectal tumors, we analyzed the nuclear
expression of these proteins in resected colorectal tumors
by immunohistochemistry. We also analyzed the expres-
sion of MMP7, which has functional AP-1 and TCF bind-
ing sites in its promoter [19].
Methods
Tumor specimens
Primary tumor specimens from 68 colorectal tumors were
consecutively obtained by surgery or endoscopically from
the Hokkaido University Medical Hospital between 2000
and 2003. Informed consent from patients were obtained
for the use of resected tumor specimens. The patients with
colorectal tumors consisted of 35 men and 33 women,
with an average age at diagnosis of 63.8 years. The tumor
classifications were determined according to the guide-
lines of the International Agency for Research on Cancer
(IARC) and World Health Organization (WHO) [20].
Tumor specimens were histopathologically diagnosed as
adenomas (n = 19), high-grade intraepithelial neoplasia
(HGINs) (n = 14) and adenocarcinomas (n = 35). The
pTNM classifications were determined according to the
guidelines of the International Union Against Cancer
(UICC) [21]. Adenocarcinoma represented 9 pT1, 2 pT2,
19 pT3 and 5 pT4 stage tumors, and 20 pN0, 7 pN1, 6 pN2
and 2 pN3 stage tumors.
Antibodies
The primary antibodies used for immunohistochemistry
and immunofluorescence analyses included a rabbit pol-
yclonal antibody to p-c-Jun (Phospho-c-Jun (Ser63) II;
Cell Signaling, Cumming Center Beverly, MA) which rec-
ognizes c-Jun phosphorylated at Ser 63 [22,23], a mouse
anti-β-Catenin monoclonal antibody (IgG1, Clone 14;
Transduction Laboratories, San Diego, CA) [24-28], a
mouse anti-Tcf-4 monoclonal antibody (IgG2a, 6H5-3;
Sigma, St. Louis, Missouri) [29] and a mouse anti-human
MMP7 monoclonal antibody (IgG1, Clone 141-7B2; Dai-
ichi Fine Chemical, Toyama, Japan) [30,31].
Immunohistochemistry analysis
Expression of p-c-Jun, TCF4, β-Catenin, and MMP7 was
analyzed by immunohistochemistry. The avidin-biotin-
peroxidase complex (ABC) method was used on 4-μm sec-
tions of formalin-fixed, paraffin-embedded tissues after
deparaffinization. Briefly, deparaffinized tissue sections
were microwaved in 0.01 M sodium citrate (pH 6.0) to
retrieve the antigenicity for 25 min for p-c-Jun or 20 min
for TCF4, β-Catenin and MMP7. The slides were allowed
to cool for an additional 20 min in citrate buffer. The sec-
tions were then incubated with 3% (w/v) H2O2 in metha-
nol to inhibit endogenous peroxidase activity, followed
by incubation with normal goat serum (Vectastain Elite
ABC kit; Vector Laboratories, Burlingame, CA) for p-c-Jun
or with normal horse serum (Vectastain Elite ABC kit) for
β-Catenin, TCF4 and MMP7 for 30 min at room tempera-
ture to block the nonspecific antibody binding sites. The
sections were consecutively reacted with a rabbit polyclo-
nal antibody against p-c-Jun (1:50 dilution) or with a
mouse monoclonal antibody against TCF4 (1:200 dilu-
tion), β-Catenin (1:3200 dilution), or MMP7 (1:400 dilu-
tion) at 4°C overnight. After washing, biotinylated goat
anti-rabbit IgG antibody (Vectastain Elite ABC kit) for p-
c-Jun or biotinylated horse anti-mouse IgG antibody
(Vectastain Elite ABC kit) for β-Catenin, TCF4 and MMP7BMC Cancer 2008, 8:328 http://www.biomedcentral.com/1471-2407/8/328
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was applied for 30 min. After washing, avidin-biotin-per-
oxidase complex (Vectastain Elite ABC kit) was applied for
30 min followed by peroxidase detection with a mixture
of 3,3'-diaminobenzidine (DAB; Vector Laboratories). To
determine specificity of immunostaining, serial sections
were similarly processed except that primary antibodies
were omitted. Sections were counterstained with methyl
green.
Immunohistochemical evaluation
Two investigators (K.T. and I.K.) separately and independ-
ently evaluated the immunohistochemical staining with-
out knowledge of the clinical data. The results were
evaluated as immunohistochemistry (IHC) score, where
the IHC score = (percentage of positive cells (percentage
score)) × (staining intensity [which was scored as 0 to 3])
[26,27,32]. Significant differences in interpretation were
resolved in conference. Such differences in interpretation
only occurred in a small subset of specimens; discordance
more than 30% in percentage score is 24% in total speci-
mens of three types of tumors and their adjacent normal
epithelia, and discordance more than one staining inten-
sity score is 3%. Interobserver agreement on four staining
intensity scores was also evaluated using the linearly
weighted kappa statistics [33]. The kappa value was 0.46
in all cases (data not shown) and interpreted as moderate
agreement [33]. In cases without significant discordance,
scores of two observer were averaged.
Statistical analyses
Wilcoxon matched pairs signed ranks test was used to
determine the differences between the tumors and the
adjacent normal epithelia. The Mann-Whitney U test and
Kruskal-Wallis test were used to determine the difference
between two groups and among more than two groups,
respectively. p < 0.05 was considered statistically signifi-
cant. Spearman's rank correlation test was used to deter-
mine the correlation with staining intensity and
percentage score.
Immunofluorescence analysis
For the immunofluorescent staining of p-c-Jun, TCF4 and
β-Catenin, the sections were subjected to antigen retrieval
by heating in 0.01 M sodium citrate (pH 6.0) in a micro-
wave oven for 25 min. The slides were allowed to cool for
an additional 20 min in citrate buffer. The sections were
permeabilized in PBS containing 0.2% Triton X-100
(PBT) for 20 min at room temperature. Nonspecific bind-
ing sites were blocked with normal goat serum for 30 min
at room temperature. The sections were incubated at 4°C
overnight with a combination of the primary rabbit poly-
clonal antibody against p-c-Jun (1:2 dilution) and one of
the mouse monoclonal antibodies against TCF4 (1:4 dilu-
tion) and β-Catenin (1:60 dilution). After washing, the
sections were incubated for 90 min at room temperature
with the mixture of Alexa Fluor 488-conjugated goat anti-
rabbit IgG antibody and Alexa Fluor 568-conjugated goat
anti-mouse IgG antibody which were highly cross-
absorbed (Invitrogen, Eugene, OR). The sections were
then evaluated and photographed under a fluorescence
microscope. To determine specificity of the immunofluo-
rescent staining, serial sections were similarly processed
except that primary antibodies were omitted.
Results
Nuclear expression of p-c-Jun, TCF4, and β-Catenin in 
colorectal adenomas, HGINs and adenocarcinomas 
compared with adjacent normal colon epithelia
In the tumor cells of adenomas, HGINs and adenocarci-
nomas, staining for p-c-Jun was mainly detected in the
nucleus, while staining was observed in the nucleus and
cytoplasm for TCF4, and in the nucleus, cytoplasm and
cellular membrane for β-Catenin. Staining for MMP7 was
observed in the cytoplasm of the tumor cells. Representa-
tive immunostaining patterns for these proteins are
shown in Fig. 1. Intensity of the nuclear stainings for p-c-
Jun, TCF4 and β-Catenin, and that of the cytoplasmic
staining for MMP7 were scored as 0, 1, 2, or 3 (none,
weak, moderate, or strong). Significant immunostaining
was not detected in serial sections when the primary anti-
bodies were omitted (data not shown).
p-c-Jun, TCF4 and β-Catenin in the adenomas, and p-c-
Jun and β-Catenin in the HGINs and adenocarcinomas
showed significantly higher scores than in their adjacent
normal colorectal epithelia, respectively (p < 0.05 by Wil-
coxon matched pairs signed ranks test) (Additional file 1-
Supplemental Table S1). TCF4 in HGINs also tended to
have higher scores than in the adjacent epithelia.
Although we used IHC scores (see Methods) to evaluate
results, high correlations were observed for each proteins
between staining intensity and percentage score in adja-
cent normal epithelia and tumors of all three types (Addi-
tional file 2-Supplemental Table S2), which prompted us
to see if the results would be similar when percentage
score were used for evaluation. Using the percentage
score, we observed similar results, and the difference of
TCF4 between HGINs and adjacent normal epithelia also
reached significance. (p < 0.05 by Wilcoxon matched pairs
signed ranks test) (Additional file 3-Supplemental Table
S3).
Nuclear expression of p-c-Jun, TCF4, and β-Catenin 
among adenomas, HGINs and adenocarcinomas
Nuclear expression of p-c-Jun, TCF4 and β-Catenin was
compared among the adenomas, HGINs and adenocarci-
nomas (Fig. 2). Only p-c-Jun expression was significantly
different (p = 0.02 by Kruskal-Wallis test); adenomas and
HGINs had higher scores than adenocarcinomas. ThereBMC Cancer 2008, 8:328 http://www.biomedcentral.com/1471-2407/8/328
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were no differences in the expression of TCF4 and β-Cat-
enin among them. We observed the similar results when
we used the percentage scores (p = 0.01 by Kruskal-Wallis
test) (Additional file 4-Supplemental Figure S1).
Relationship between nuclear expression of p-c-Jun, TCF4 
and β-Catenin, and pT and pN stages in adenocarcinomas
We analyzed the nuclear expression of p-c-Jun, TCF4 and
β-Catenin in relation to the pT and pN stages in adenocar-
cinomas. We observed significantly lower p-c-Jun expres-
sion in tumors having the higher pT stage (p = 0.0006 by
Mann-Whitney U test) (Fig. 3). Expression of TCF4 and β-
Catenin was not significantly correlated with the pT stage.
There was no significant correlation of expression of p-c-
Jun, TCF4, and β-Catenin with the pN stage (Fig. 3). We
observed the similar results including significantly lower
p-c-Jun expression in tumors having the higher pT stage
when we used percentage scores (p = 0.0009 by Mann-
Whitney U test) (Additional file 5-Supplemental Figure
S2).
Correlation between the nuclear expression of p-c-Jun, 
TCF4 and β-Catenin, and cytoplasmic MMP7 expression
To investigate the relationships of p-c-Jun, TCF4, and β-
Catenin with MMP7, whose promoter contains both func-
tional AP-1 and TCF binding sites [19], we analyzed the
correlation of the nuclear expression of p-c-Jun, TCF4 and
β-Catenin with cytoplasmic MMP7 expression in colorec-
tal tumors including adenomas, HGINs and adenocarci-
nomas. Significant correlations of exprssion were
observed between p-c-Jun and TCF4 (r = 0.25, p = 0.04),
and TCF4 and β-Catenin (r = 0.30, p = 0.01), p-c-Jun and
MMP7 (r = 0.26, p = 0.03), and TCF4 and MMP7 (r = 0.39,
p = 0.0008), respectively (Table 1).
Representative immunohistochemical staining patterns for p-c-Jun, TCF4, β-Catenin, and MMP7 Figure 1
Representative immunohistochemical staining patterns for p-c-Jun, TCF4, β-Catenin, and MMP7. High-power 
view of representation area in each tumor is shown in a box. The staining intensity in the nucleus of tumor cells for p-c-Jun, 
TCF4 and β-Catenin and in the cytoplasm of the tumor cells for MMP7 was categorized as 0, 1, 2, or 3 (none, weak, moderate, 
or strong).BMC Cancer 2008, 8:328 http://www.biomedcentral.com/1471-2407/8/328
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Immunofluorescence analysis of p-c-Jun, TCF4 and β-
Catenin
To determine whether p-c-Jun, TCF4 and β-Catenin are
colocalized in the nuclei, several specimens of adenocar-
cinoma that expressed each protein were examined by
immunofluorescence. A representative specimen demon-
strated that p-c-Jun and TCF4 were colocalized predomi-
nantly in the nuclei in a majority of the tumor cells.
Although β-Catenin was predominantly located in the cel-
lular membrane of the tumor cells, it was also colocalized
with p-c-Jun in some parts of the nuclei (Fig. 4). Signifi-
cant immunofluorescent staining was not detected in
serial sections when the primary antibodies were omitted
(data not shown).
Discussion
A recent study has shown that p-c-Jun interacts with TCF4
to form a complex that cooperatively enhances the tran-
scriptional activity in the presence of β-Catenin, and that
this interaction is critical for mouse intestinal tumorigen-
esis [17]. However, only a few studies have examined c-
Jun, TCF4 and β-Catenin expression in human colorectal
tumors [17,26-29]. In addition, there have been no stud-
ies that have analyzed their expression within the same
specimens of human colorectal tumors. In the present
study, we demonstrated that p-c-Jun, TCF4 and β-Catenin
are frequently overexpressed in the nucleus of resected
human colorectal tumors when compared to the adjacent
normal epithelia by immunohistochemistry, suggesting
that these three proteins may play important roles in
human colorectal tumor development. The high expres-
sion of p-c-Jun in adenomas and HGINs, as compared
with adenocarcinomas, and its negative correlation with
pT stage progression in adenocarcinomas suggest that p-c-
Jun may play a pivotal role in the earlier stages of tumor
development. Furthermore, the multiple correlations
among the expressions of these three proteins and MMP7,
which is one of their downstream gene products, suggest
that the interactions of p-c-Jun, TCF4 and β-Catenin that
have been demonstrated in vitro [19] are also important
in human colorectal tumor development.
Expression of c-Jun has been shown to be elevated in
human colorectal adenomas and carcinomas when com-
pared to adjacent normal epithelia [34]. c-Jun's transcrip-
tional activity is enhanced through the N-terminal
phosphorylation of c-Jun at the serin residues 63 and 73
by JNKs [16]. The present findings that the active phos-
phorylated form of c-Jun is also elevated in colorectal ade-
noma and carcinoma further support a potential role for
c-Jun in human colorectal tumors.
While the published studies on c-Jun have not explored
the correlations with pathological stages in adenocarci-
noma [34], we have shown the higher p-c-Jun expression
in adenomas and HGINs than in adenocarcinomas, and
its negative correlation with pT stage progression in inva-
sive cacinomas. The correlation of p-c-Jun expression with
the earlier stages of human tumorigenesis is consistent
with the recent in vivo studies for intestinal and liver
Nuclear expression of p-c-Jun, TCF4 and β-Catenin in adenomas (n = 19), HGINs (n = 14) and adenocarcinomas (n = 35) Figure 2
Nuclear expression of p-c-Jun, TCF4 and β-Catenin in adenomas (n = 19), HGINs (n = 14) and adenocarcino-
mas (n = 35). Only p-c-Jun expression was significantly different. Adenomas and HGINs showed higher immunohistochemis-
try (IHC) scores than adenocarcinomas. Horizontal lines, median; boxes, 25% to 75% range; brackets, 10% to 90% range; 
circles, points outside the 10% to 90% range. *p < 0.05 by Kruskal-Wallis test.
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tumors [17,35,36]. In the ApcMin mouse model of intesti-
nal cancer, genetic abrogation of the c-Jun N-terminal
phosphorylation or gut-specific conditional c-jun inacti-
vation reduces tumor number and size, and prolongs the
lifespan [17]. In the mouse model of the chemically
induced hepatocellular carcinomas, c-jun is required for
the early stages of tumor development, and the number
and size of hepatic tumors is dramatically reduced by c-
jun inactivation after the tumors have been initiated
[35,36]. Furthermore, in human lung tumorigenesis, c-
Jun is frequently overexpressed in an atypical area that
includes dysplasia, and less frequently in lung cancer [37].
Relationship between nuclear expression of p-c-Jun, TCF4 and β-Catenin and the pT and pN stages in adenocarcinomas (n =  35) Figure 3
Relationship between nuclear expression of p-c-Jun, TCF4 and β-Catenin and the pT and pN stages in adeno-
carcinomas (n = 35). a) p-c-Jun expression was significantly negatively correlated with the pT stage progression (T1-2, n = 
11; T3-4, n = 24). b) No significant correlation was observed between p-c-Jun, TCF4 and β-Catenin expression, and the pN 
stage (N0, n = 20; N1-3, n = 15). Horizontal lines, median; boxes, 25% to 75% range; brackets, 10% to 90% range; circles, 
points outside the 10% to 90% range. *p < 0.05 by Mann-Whitney U test.
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Taken together, these results suggest that c-Jun, especially
in its phosphorylated state, may play a pivotal role in the
early stages of the tumor development, including that of
human colorectal tumors.
The similarly high levels of expression of TCF4 in the
nucleus of the colorectal normal epithelia and adenocar-
cinomas are consistent with the results of previous studies
by immunohistochemistry and in situ hybridization
[29,38]. Interestingly, we found that the nuclear expres-
sion of TCF4 is significantly higher in adenomas than in
the adjacent normal epithelia. Korinek et. al. [38] demon-
strates that Apc-/- colon carcinoma cells contain a stable
and constitutively active β-Catenin-TCF4 complex in the
nuclei and that reintroduction of APC removes β-Catenin
from TCF4 and abrogates the transcriptional activation of
TCF4. These in vitro findings suggest that constitutive
transcription of the TCF target genes, which is caused by
the loss of APC function, may be a crucial event in the
early transformation of the colonic epithelium. In this
study, β-Catenin is also expressed in the nuclei in human
colorectal adenomas and carcinomas including HGINs, as
reported previously [26,27,39]. The elevated nuclear
expression of both TCF4 and β-Catenin is in line with
their theorized roles in early colorectal carcinogenesis.
Multiple correlations of expressions among p-c-Jun, TCF4
and β-Catenin, and their colocalization within nucleus
shown by immunofluorescence analysis are consistent
with two recent in vitro studies [17,18]. One shows that p-
c-Jun interacts with TCF4 to form a ternary complex con-
taining c-Jun, TCF4 and β-Catenin and that p-c-Jun and
TCF4 cooperatively activate the c-jun promoter in a β-Cat-
enin-dependent manner [17]. The other shows that the
Table 1: Correlation among expression of p-c-Jun, TCF, β-
Catenin and MMP7 in all colorectal tumors (n = 68).
Factors R p
p-c-Jun/TCF4 0.25 0.04*
p-c-Jun/β-Catenin 0.13 0.3
p-c-Jun/MMP7 0.26 0.03*
TCF4/β-Catenin 0.30 0.01*
TCF4/MMP7 0.39 0.0008*
β-Catenin/MMP7 0.05 0.6
*p < 0.05 by Pearson's correlation test
Immunofluorescence analysis of p-c-Jun, TCF4 and β-Catenin in a representative specimen of adenocarcinoma Figure 4
Immunofluorescence analysis of p-c-Jun, TCF4 and β-Catenin in a representative specimen of adenocarci-
noma. Upper panels: p-c-Jun (Alexa 488; green) and TCF4 (Alexa 568; red) were colocalized predominantly in the nuclei in 
the majority of the tumor cells. Lower panels: β-Catenin (Alexa 568; red) was colocalized in some parts of the nuclei with p-c-
Jun (Alexa 488; green), although β-Catenin was predominantly located in the cellular membrane of the tumor cells.
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armadillo repeat domain of β-Catenin physically associ-
ates with the DNA-binding domain of c-Jun and that β-
Catenin target genes, cyclin D1 and c-myc, are transcrip-
tionally activated by c-Jun through TCF-binding site [18].
Both studies show these interactions cooperatively
enhance their transcriptional activities of promoters con-
taining AP-1 and TCF-binding sites including c-jun pro-
moter itself, which can promote a positive feedback loop
for c-Jun expression, consistent with their correlations
observed in human colorectal tumors. Significantly corre-
lated expression of p-c-Jun and TCF4 with MMP7, which
has functional AP-1 site and TCF4 site in its promoter
[19], may support the hypothesis that interaction of p-c-
Jun, TCF4 and β-Catenin enhance transcriptional activity
and that the interaction is also important in human color-
ectal carcinogenesis.
Conclusion
These results suggest that nuclear expression of p-c-Jun,
TCF4 and β-Catenin have important roles in human
colorectal tumor development and that p-c-Jun may play
a pivotal role in the earlier stages of this tumor develop-
ment. Small molecule inhibitors of JNKs have been
shown to inhibit c-Jun phosphorylation and the phos-
phorylation-dependent interactions between c-Jun and
TCF4 [17]. AP-1 blockade by a c-Jun dominant-negative
mutant has been shown to inhibit growth of cancer cells
includes colon cancer cells [40,41]. Such inhibitors may
have potential for use as preventive and therapeutic strat-
egies against colorectal cancers.
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